Kidney cancer in 2013: From molecular understanding to clinical advances
Carcinoma, Renal Cell
Hypoxia-Inducible Factor 1
Von Hippel-Lindau Tumor Suppressor Protein
Big data and computational biology brought to the forefront a number of potential actionable mutations and drug targets in clear cell renal cell carcinoma in 2013. As we continue to unravel the molecular underpinnings of tumorigenesis and progression, the clinical benefits will eventually be reaped.